IGC Pharma (NYSEAMERICAN:IGC) Shares Pass Above 200-Day Moving Average of $0.00

IGC Pharma, Inc. (NYSEAMERICAN:IGC) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.45. IGC Pharma shares last traded at $0.40, with a volume of 203,923 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on IGC Pharma in a research report on Monday, May 6th. They set a “sell” rating on the stock.

IGC Pharma Stock Performance

The company has a quick ratio of 0.86, a current ratio of 1.85 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $26.79 million, a price-to-earnings ratio of -1.54 and a beta of 1.51.

IGC Pharma Company Profile

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.